MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily ...

Scientists are making rapid progress toward a long-awaited goal that could help to reshape cancer care: mRNA cancer vaccines with the potential to significantly boost the immune system’s ability to ...

Tommy Cannon shares prostate cancer update with fans and urges men to get tested - The comedian also recalled a particularly distressing moment during an MRI scan when the machine ‘broke down’ ...

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically ...

A Supreme Court judge weighed up supposed DNA evidence, allegations of violent sexual assault and a voicemail of a complainant ‘hysterically crying’ before granting bail to a 65-year-old Lake Cathie ...

First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total ...

Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of ...

Photographer Ken Amer is urging men and their families across Orkney to start a simple but potentially life-saving conversation this Prostate Cancer Awareness Month. Four years after being diagnosed ...

Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipat ...

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a clinical-stage biotechnology company developing a pipeline of ...

State data from 2018 through 2022 shows prostate cancer is the leading cancer diagnosis in Cuyahoga County, yet 77% of cases ...

Early-stage prostate cancer rarely causes symptoms, making routine screening the most reliable way to catch it before it ...